ALCAM
ALCAMproteinALCAM on circulating vesicles enhances leukocyte–endothelial adhesion and platelet–leukocyte coupling in acute MI.
Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleAdhesion molecule enriched in AMI extracellular vesicles; leukocyte recruitment.
Also acts inPlatelet activation
Druggability
DruggableYes
Known drugs / candidates1
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000170017
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I20
C — confounder / Type-II36
A — assay feasibility72
E — evidence strength14
T1DI (composite)4
Specificity differential (R−C)-15.9
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- DSCAML1+ extracellular vesicles revealed by single-vesicle proteomics as a novel biomarker and therapeutic target in myocardial infarction.Journal of nanobiotechnology · 2026 · PMID 41872860 · doi